You are here: Industry Insights > Farxiga

News List

Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure worldpharmanews
August 21, 2019
AstraZeneca announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint with a statistically-significant and ...
Farxiga Meets Primary Endpoint in Heart Failure Trial americanpharmaceuticalreview
August 21, 2019
AstraZeneca has announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint with a statistically-significant and clinically-meaningful reduction of ...
FDA rejects AstraZeneca’s Farxiga treatment europeanpharmaceuticalreview
July 17, 2019
AstraZeneca has been issued with a complete response letter for Farxiga by the FDA meaning that it has rejected the treatment.
AstraZeneca's Farxiga chops follow-up CV events by 16% in heart attack patients with diabetes fiercepharma
March 19, 2019
AstraZeneca is stepping up its case for its SGLT2 diabetes drug Farxiga with new numbersshowing it can cut the risk of serious cardiovascular complications in heart attack and heart failure patients.
AZ’ Farxiga shows CV benefit in diabetes patients pharmatimes
March 19, 2019
Trial data show that AstraZeneca’s Farxiga (dapagliflozin) cut the relative risk of major adverse cardiovascular events (MACE) by 16% compared to placebo in patients with type II diabetes who had a prior heart attack.

Previous page 1 2 3 Next page